Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | HRH2 | P25021 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2114234 | 1.00 | GRIN1 (0.33) | GRIN1GRIN2BLTA4HCHRM2CHRM3 | |
| SCHEMBL19616664 | 1.00 | GRIN1 (0.33) | GRIN1GRIN2BLTA4HCHRM2CHRM3 | |
| SCHEMBL6044051 | 0.95 | HTR4 (0.34) | GRIN1GRIN2BLTA4HCHRM2CHRM3 | |
| SCHEMBL2116532 | 0.89 | ACHE (0.39) | ACHEMAOB | |
| SCHEMBL6043379 | 0.89 | SLC18A3 (0.37) | GRIN1GRIN2BLTA4HKMT2A | |
| SCHEMBL2116387 | 0.89 | HRH3 (0.37) | CHRM3ACHEMAOBHRH1MEN1 | |
| SCHEMBL15685468 | 0.89 | SLC18A3 (0.37) | GRIN1GRIN2BLTA4HKMT2A | |
| SCHEMBL15685469 | 0.89 | SLC18A3 (0.37) | GRIN1GRIN2BLTA4HKMT2A | |
| Hydrochloric Acid SCHEMBL25364283 | 0.87 | SLC18A3 (0.36) | GRIN1GRIN2BLTA4HLMNA | |
| SCHEMBL14968346 | 0.84 | GBA1 (0.38) | MEN1KMT2ASIGMAR1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3929203-A1 | DERIVATIVES OF AMPHOTERICIN B | Sfunga Therapeutics, Inc. (US) | 2021-12-29 | — | — | EP | disclosed |
| EP-3283171-B1 | DERIVATIVES OF AMPHOTERICIN B | SFUNGA THERAPEUTICS INC (US) | 2021-05-26 | — | — | EP | disclosed |
| US-10882883-B2 | Derivatives of amphotericin B | SFUNGA THERAPEUTICS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20200262858-A1 | DERIVATIVES OF AMPHOTERICIN B | ELION THERAPEUTICS, INC. | 2020-08-20 | — | — | US | disclosed |
| US-9957290-B2 | Derivatives of amphotericin B | SFUNGA THERAPEUTICS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9957290-B2 | Derivatives of amphotericin B | SFUNGA THERAPEUTICS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| WO-2016168568-A1 | DERIVATIVES OF AMPHOTERICIN B | Revolution Medicines, Inc. (US) | 2016-10-20 | — | — | WO | disclosed |
| US-20160304548-A1 | Derivatives of Amphotericin B | ELION THERAPEUTICS, INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160304548-A1 | Derivatives of Amphotericin B | ELION THERAPEUTICS, INC. | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304548-A1 | Derivatives of Amphotericin B | C9, ERG28, AMPD3 | GRIN1 4220/4885GRIN2B 2608/4885LTA4H 1251/4885 |
| US-10882883-B2 | Derivatives of amphotericin B | C9, ERG28, AMPD3 | GRIN1 4220/4885GRIN2B 2608/4885LTA4H 1251/4885 |
| US-20200262858-A1 | DERIVATIVES OF AMPHOTERICIN B | C9, ERG28, AMPD3 | GRIN1 4220/4885GRIN2B 2608/4885LTA4H 1251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.